Exclusive Summary

• - Patent barriers cleared globally: LMWH originators launched in the 1990s, with EU generics mid‑2000s and US entry since 2010.
• - Large and steady demand: ~10 million VTE cases yearly, ~310 million major surgeries, and ~4 million dialysis patients, plus pregnancy use cases.
• - Clear standard-of-care status: LMWH (e.g., enoxaparin) is on the WHO Essential Medicines List and is guideline-preferred for inpatient prophylaxis, pregnancy, and cancer-associated thrombosis.
• - Quality/registration strengths: API meets BP/EP/USP, CTD/DMF-ready with traceable porcine supply chain, aligning with multi-country registration and tender needs.
• - Compelling cost savings: typically 30–70% cheaper vs originators, suited for centralized tenders and payer cost containment.